Natixis Advisors, L.P. Collegium Pharmaceutical, Inc Transaction History

Natixis Advisors, L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$31.36 - $39.99 $102,986 - $131,327	-3,284 Reduced 11.75%	24,665 $794,000
Q1 2024 Apr 25, 2024	BUY	$31.23 - $40.91 $1,967 - $2,577	63 Added 0.23%	27,949 $1.09 Million
Q4 2023 Feb 06, 2024	SELL	$21.16 - $30.8 $560,168 - $815,368	-26,473 Reduced 48.7%	27,886 $858,000
Q3 2023 Nov 13, 2023	BUY	$21.23 - $24.28 $697,723 - $797,962	32,865 Added 152.9%	54,359 $1.22 Million
Q2 2023 Aug 15, 2023	BUY	$21.06 - $24.0 $452,663 - $515,856	21,494 New	21,494 $462,000
Q4 2020 Feb 12, 2021	SELL	$17.83 - $22.29 $1.61 Million - $2.01 Million	-90,189 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$15.78 - $20.82 $80,478 - $106,182	5,100 Added 5.99%	90,189 $1.88 Million
Q2 2020 Aug 11, 2020	BUY	$15.49 - $23.51 $166,532 - $252,756	10,751 Added 14.46%	85,089 $1.49 Million
Q1 2020 Apr 27, 2020	BUY	$13.89 - $25.45 $1.03 Million - $1.89 Million	74,338 New	74,338 $1.21 Million

249

36.2M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.11B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

Stay updated on Natixis Advisors, L.P. with notifications on news.